Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Merck
AstraZeneca
Johnson and Johnson
Fish and Richardson
Deloitte
McKinsey

Generated: September 22, 2019

DrugPatentWatch Database Preview

Patent: 10,292,951

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,292,951
Title:Methods and compositions for treating conditions associated with an abnormal inflammatory responses
Abstract: This disclosure features chemical entities (e.g., a compound exhibiting activity as a mitochondrial uncoupling agent or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as niclosamide or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as a niclosamide analog, or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof) that are useful, e.g., for treating one or more symptoms of a pathology characterized by an abnormal inflammatory response (e.g., inflammatory bowel diseases) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.
Inventor(s): Glick; Gary D. (Ann Arbor, MI), Franchi; Luigi (Ann Arbor, MI), Santus; Giancarlo (Milan, IT)
Assignee: First Wave Bio, Inc. (Ann Arbor, MI)
Application Number:15/255,102
Patent Claims:see list of patent claims

Details for Patent 10,292,951

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Try a Free Trial First Wave Bio, Inc. (Ann Arbor, MI) 2035-09-01 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Try a Free Trial First Wave Bio, Inc. (Ann Arbor, MI) 2035-09-01 RX search
Bristol Myers Squibb YERVOY ipilimumab INJECTABLE; INJECTION 125377 001 2011-03-25   Try a Free Trial First Wave Bio, Inc. (Ann Arbor, MI) 2035-09-01 RX search
Merck Sharp Dohme KEYTRUDA pembrolizumab POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER 125514 001 2014-09-04   Try a Free Trial First Wave Bio, Inc. (Ann Arbor, MI) 2035-09-01 RX Orphan search
Bristol Myers Squibb OPDIVO nivolumab INJECTABLE;INJECTION 125527 001 2015-03-04   Try a Free Trial First Wave Bio, Inc. (Ann Arbor, MI) 2035-09-01 RX search
Bristol Myers Squibb OPDIVO nivolumab INJECTABLE;INJECTION 125527 002 2015-03-04   Try a Free Trial First Wave Bio, Inc. (Ann Arbor, MI) 2035-09-01 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Medtronic
Citi
Fuji
Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.